间氯苯甘氨酸 | 7292-71-9

• 物质功能分类: 生物化工 - 常见氨基酸及蛋白质类
• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 间氯苯甘氨酸
• 中文别名: DL-2-(3-氯苯基)甘氨酸
• 英文名称: 2-(3-chlorophenyl)glycine
• 英文别名: 2-amino-2-(3-chlorophenyl)acetic acid；3-chlorophenylglycine；DL-m-chlorophenylglycine；D,L-α-Amino-3-chlorphenylessigsaeure；m-Chlor-phenylglycin；2-azaniumyl-2-(3-chlorophenyl)acetate
• CAS: 7292-71-9
• 化学式: C₈H₈ClNO₂
• mdl: MFCD00049326
• 分子量: 185.61
• InChiKey: MGOUENCSVMAGSE-UHFFFAOYSA-N

物化性质

• 熔点：
  268-269℃ (decomposition)
• 沸点：
  316.9±32.0 °C(Predicted)
• 密度：
  1.392±0.06 g/cm3(Predicted)
• 溶解度：
  可溶于酸水溶液（轻微），甲醇（非常轻微，加热）

计算性质

• 辛醇/水分配系数(LogP)：
  -1.1
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.125
• 拓扑面积：
  63.3
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335
• 储存条件：
  室温，惰性气体氛围

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: Amino-(3-chloro-phenyl)acetic acid
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: Amino-(3-chloro-phenyl)acetic acid
CAS number: 7292-71-9

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C8H8ClNO2
Molecular weight: 185.6

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen chloride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

2-氨基-2-(3-氯苯基)乙酸是甘氨酸（HY-Y0966）的一种衍生物。

反应信息

• 作为反应物：
  描述：

  间氯苯甘氨酸 在 lithium aluminium tetrahydride 作用下， 以 四氢呋喃 为溶剂， 反应 5.0h， 生成 (R)-3-氯苯基氨基醇
  参考文献：
  名称：

  N-未受保护的氮丙啶与 α-氧代烯酮的无催化剂亲电环扩展以有效访问 2-亚烷基-1,3-恶唑烷

  摘要：

  2-(2-氧代亚烷基)-1,3-恶唑烷衍生物通过无催化剂的N-未保护氮丙啶和α-氧代烯酮的烯酮C=O双键的无催化剂亲电子环膨胀，以良好到优异的产率区域特异性地合成，原位由 2-重氮-1,3-二酮的微波辅助沃尔夫重排产生。环膨胀主要经历了 S N 1 过程，氢键决定了产物的 ( E )-构型。

  DOI：

  10.1002/adsc.202100320
• 作为产物：
  描述：

  5-(3-氯-苯基)-咪唑烷-2,4-二酮 在 potassium carbonate 作用下， 以 水 为溶剂， 178.0 ℃ 、2.5 MPa 条件下， 反应 0.07h， 生成 间氯苯甘氨酸
  参考文献：
  名称：

  一种连续快速制备DL-苯甘氨酸及其类似物的方法

  摘要：

  本发明提供一种连续快速制备DL‑苯甘氨酸及其类似的方法，包括：将2‑羟基‑苯乙腈及其类似物（简称氰醇）与碳铵水溶液加入微通道反应器进行反应，控制反应温度为80～130℃，压力为0.5～2.0MPa，反应物在微通道内停留时间为1～8min，得到5‑苯基‑乙内酰脲及其类似物（简称海因）水溶液；将海因与碱加入微通道反应器进行反应，控制反应温度为120～200℃，压力为1.0～3.5MPa，反应物在微通道内的停留时间为1～8min，得到苯甘氨酸及其类似物盐水溶液，经酸化中和、结晶，得到苯甘氨酸及其类似物。本发明采用微通道反应器，大大缩短了反应时间，加快反应速率，减少了氰醇热解聚合，无副产物产生，产品收率高，清洁环保，降低了生产成本。

  公开号：

  CN109824531B

文献信息

• [EN] HEPATITIS C VIRUS INHIBITORS<br/>[FR] INHIBITEURS DU VIRUS DE L'HÉPATITE C
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2010138488A1

  公开（公告）日：2010-12-02

  This disclosure concerns novel compounds of Formula (I) as defined in the specification and compositions comprising such novel compounds. These compounds are useful antiviral agents, especially in inhibiting the function of the NS5A protein encoded by Hepatitis C virus (HCV). Thus, the disclosure also concerns a method of treating HCV related diseases or conditions by use of these novel compounds or a composition comprising such novel compounds.

  本公开涉及规范中定义的Formula (I)的新化合物以及包含这些新化合物的组合物。这些化合物是有用的抗病毒剂，特别是在抑制由丙型肝炎病毒（HCV）编码的NS5A蛋白的功能方面。因此，本公开还涉及通过使用这些新化合物或包含这些新化合物的组合物来治疗HCV相关疾病或症状的方法。
• Access to 2-arylquinazolines <i>via</i> catabolism/reconstruction of amino acids with the insertion of dimethyl sulfoxide
  作者：Jin-Tian Ma、Li-Sheng Wang、Zhi Chai、Xin-Feng Chen、Bo-Cheng Tang、Xiang-Long Chen、Cai He、Yan-Dong Wu、An-Xin Wu

  DOI：10.1039/d1cc00623a

  日期：——

  Quinazoline skeletons are synthesized by amino acid catabolism/reconstruction combined with the insertion/cyclization of dimethyl sulfoxide for the first time. The amino acid acts as a carbon and nitrogen source through HI-mediated catabolism and is then reconstructed using aromatic amines and dimethyl sulfoxide (DMSO) as a one-carbon synthon. This protocol is of great significance for the further

  喹唑啉骨架是首次通过氨基酸分解代谢/重建结合二甲基亚砜的插入/环化合成。氨基酸通过 HI 介导的分解代谢充当碳和氮源，然后使用芳香胺和二甲基亚砜 (DMSO) 作为单碳合成子进行重建。该方案对进一步研究氨基酸转化具有重要意义。
• Enantioselective C−H Olefination of α-Hydroxy and α-Amino Phenylacetic Acids by Kinetic Resolution
  作者：Kai-Jiong Xiao、Ling Chu、Jin-Quan Yu

  DOI：10.1002/anie.201510808

  日期：2016.2.18

  development of enantioselective C−H activation reactions by desymmetrization. However, the requirement for the presence of two chemically identical prochiral C−H bonds represents an inherent limitation in scope. Reported is the first example of kinetic resolution by a palladium(II)‐catalyzed enantioselective C−H activation and C−C bond formation, thus significantly expanding the scope of enantioselective C−H

  在过去的十年中，关于通过去对称化发展对映选择性CH活化反应的研究取得了重大进展。但是，要求存在两个化学上相同的前手性CH键代表了范围上的固有限制。报道的第一个通过钯（II）催化对映选择性CH活化和CC键形成动力学拆分的例子，从而显着扩大了对映选择性CH活化反应的范围。
• Benzoxazinone-containing 3,5-dimethylisoxazole derivatives as BET bromodomain inhibitors for treatment of castration-resistant prostate cancer
  作者：Xiaoqian Xue、Yan Zhang、Chao Wang、Maofeng Zhang、Qiuping Xiang、Junjian Wang、Anhui Wang、Chenchang Li、Cheng Zhang、Lingjiao Zou、Rui Wang、Shuang Wu、Yongzhi Lu、Hongwu Chen、Ke Ding、Guohui Li、Yong Xu

  DOI：10.1016/j.ejmech.2018.04.034

  日期：2018.5

  The bromodomain and extra-terminal proteins (BET) have emerged as promising therapeutic targets for the treatment of castration-resistant prostate cancer (CRPC). We report the design, synthesis and evaluation of a new series of benzoxazinone-containing 3,5-dimethylisoxazole derivatives as selective BET inhibitors. One of the new compounds, (R)-12 (Y02234), binds to BRD4(1) with a Kd value of 110 nM

  溴结构域和末端外蛋白（BET）已成为治疗去势抵抗性前列腺癌（CRPC）的有希望的治疗靶标。我们报告设计，合成和评估的一系列新的含苯并恶嗪酮的3,5-二甲基异恶唑衍生物作为选择性BET抑制剂。一种新化合物（R）-12（Y02234）以Kd值为110 nM结合BRD4（1），并以100 nM的IC50值阻断溴结构域和乙酰赖氨酸的相互作用。它也对非BET溴结构域蛋白表现出BET选择性，并在诸如22Rv1和C4-2B的前列腺癌细胞系中显示出合理的抗增殖和集落形成抑制作用。BRD4抑制剂（R）-12还可以在前列腺癌细胞的mRNA水平上显着抑制ERG，Myc和AR目标基因PSA的表达。（R）-12处理可在22Rv1衍生的异种移植模型中显着抑制前列腺癌的肿瘤生长（TGI = 70％）。这些数据表明化合物（R）-12是用于开发用于治疗CRPC的新型疗法的有前途的先导化合物。
• MONOAMIDE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS
  申请人：Knust Henner

  公开号：US20090036422A1

  公开（公告）日：2009-02-05

  The present invention relates to compounds of formula wherein Ar, R 1 , R 2 , R 3 , R 4 , R 5 , n, o, and p are as defined herein or to pharmaceutically suitable acid addition salts, optically pure enantiomers, racemates or diastereomeric mixtures thereof. The compounds of formula I can be used for the treatment of sleep disorders, such as sleep apnea, narcolepsy, insomnia, parasomnia, jet lag syndrome, circadian rhythms disorder or sleep disorders associated with neurological diseases.

  本发明涉及以下式的化合物 其中 Ar，R 1 ，R 2 ，R 3 ，R 4 ，R 5 ，n，o和p如本文所定义 或其药用合适的酸盐、光学纯对映体、拉氏体或二对映异构体混合物。式I的化合物可用于治疗睡眠障碍，如睡眠呼吸暂停症、嗜睡症、失眠、睡眠障碍、时差综合征、昼夜节律紊乱或与神经系统疾病相关的睡眠障碍。